Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 4
Submit an article Journal homepage
209
Views
15
CrossRef citations to date
0
Altmetric
Letters to the Editor

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States

Amer M. ZeidanSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; Correspondence[email protected]
,
Rong WangCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA;
,
Cary P. GrossCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;
,
Steven D. GoreSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;
,
Scott F. HuntingtonSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;
,
Thomas PrebetSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA;
,
Gregory A. AbelDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;
,
Amy J. DavidoffCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA
&
Xiaomei MaCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA;
show all
Pages 982-985 | Received 24 May 2016, Accepted 13 Jul 2016, Published online: 25 Aug 2016

References

  • Zeidan AM, Gore SD, McNally DL, et al. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer. 2013;119:3870–3878.
  • Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440.
  • Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–1803.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
  • List AF, Bennett JM, Sekeres MA, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2014;28:1033–1040.
  • Bernal T, Martinez-Camblor P, Sanchez-Garcia J, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29:1875–1881.
  • Gangat N, Patnaik M, Begna K, et al. Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. Blood Cancer J. 2016;6:e414.
  • Fritz A, Percy C, Jack A, et al., eds. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.
  • Wang R, Gross CP, Maggiore RJ, et al. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Leuk Res. 2011;35:904–908.
  • Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720–2726.
  • Zeidan AM, Sekeres MA, Garcia-Manero G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016;30:649–657.
  • Zeidan AM, Davidoff AJ, Long JB, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016; [In press].
  • Lee JH, Choi Y, Kim SD, et al. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome. Ann Hematol. 2013;92:889–897.
  • Garcia-Delgado R, de Miguel D, Bailen A, et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk Res. 2014;38:744–750.
  • Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117:403–411.
  • Grinblatt DL, Sekeres MA, Komrokji RS, et al. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. Leuk Lymphoma. 2015;56:887–895.
  • Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100:1542–1551.
  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.